Clinical Trials Search
Clinical Trial 20491
Cancer Type: Malignant Hematology
Study Type: Treatment
NCT#: NCT04167514
Phase: Phase III
Prinicipal Investigator: Joseph Pidala
Study Title
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
Summary
Study CSL964_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD
Objective
The primary objective of this trial is to compare the rate of complete response (CR) and partial response (PR) on Day 28 post-randomization between AAT and CS versus placebo to match (PTM) and CS in patients with high-risk acute GVHD. Secondary objectives are to assess the following: 1. Duration of response at 6 and 12 months postrandomization. 2. Cumulative incidence of non-relapse mortality (NRM) at 6 and 12 months post-randomization. 3. Overall survival (OS) and progression free survival (PFS) at 6 and 12 months post-randomization. 4. GVHD-free survival at Day 56 post-randomization. 5. Proportions of CR, very good partial response (VGPR), PR, and treatment failure (TF) at Day 7, 14, 21, 28, 56, and 86 post-randomization. 6. Incidence of systemic infections to assess safety. 7. Incidence of Adverse Events (AEs) at 30 days post last dose of drug to assess safety. 8. Incidence of chronic GVHD at 6 and 12 months post randomization and stem cell infusion (Day 0 HCT). 9. Incidence of disease relapse at 6 and 12 months post randomization.
Therapies
Medications
Alpha 1 - Antitrypsin (); Methylprednisolone (); Placebo (); prednisone ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.